$1.78 EPS Expected for AbbVie Inc. (ABBV); Entegris Has 1.3 Sentiment

March 23, 2018 - By Vivian Park

Entegris, Inc. develops, manufactures, and supplies micro contamination control products, specialty chemicals, and advanced materials handling solutions for manufacturing processes in the semiconductor and other high-technology industries worldwide. The company has market cap of $5.13 billion. The firm operates in three divisions: Specialty Chemicals and Engineered Materials, Advanced Materials Handling, and Microcontamination Control. It has a 61.61 P/E ratio. The Specialty Chemicals and Engineered Materials segment provides high-performance and high-purity process chemistries, gases, and materials, as well as safe and efficient delivery systems to support semiconductor and other advanced manufacturing processes.

Analysts expect AbbVie Inc. (NYSE:ABBV) to report $1.78 EPS on April, 26.They anticipate $0.50 EPS change or 39.06% from last quarter’s $1.28 EPS. ABBV’s profit would be $2.82 billion giving it 13.86 P/E if the $1.78 EPS is correct. After having $1.48 EPS previously, AbbVie Inc.’s analysts see 20.27% EPS growth. The stock increased 0.56% or $0.55 during the last trading session, reaching $98.65. About 1.12M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since March 23, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 22 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 10 Hold. Therefore 45% are positive. Abbvie Inc had 81 analyst reports since July 21, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of ABBV in report on Monday, January 29 with “Hold” rating. As per Friday, July 14, the company rating was maintained by Jefferies. The firm has “Market Perform” rating by Cowen & Co given on Monday, June 6. On Friday, April 28 the stock rating was maintained by BMO Capital Markets with “Hold”. The firm earned “Equal-Weight” rating on Wednesday, June 8 by Morgan Stanley. Jefferies maintained the shares of ABBV in report on Thursday, January 4 with “Buy” rating. The firm has “Buy” rating given on Tuesday, February 23 by Citigroup. Argus Research maintained the shares of ABBV in report on Friday, February 2 with “Buy” rating. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) on Sunday, July 30 with “Hold” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Thursday, September 28 by Piper Jaffray.

Since September 28, 2017, it had 0 insider purchases, and 13 sales for $49.94 million activity. Shares for $119,351 were sold by Michael Robert A.. The insider GONZALEZ RICHARD A sold $976,084. The insider SALEKI-GERHARDT AZITA sold 1,337 shares worth $157,458. On Wednesday, February 28 the insider RICHMOND TIMOTHY J. sold $2.15 million. On Wednesday, February 28 ALBAN CARLOS sold $9.57M worth of AbbVie Inc. (NYSE:ABBV) or 83,574 shares. 18,300 shares were sold by Gosebruch Henry O, worth $1.66M on Monday, October 30. Another trade for 145,510 shares valued at $14.07M was sold by Schumacher Laura J.

Investors sentiment decreased to 0.8 in Q3 2017. Its down 0.05, from 0.85 in 2017Q2. It is negative, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Wisconsin-based Winch Advisory Services Limited Liability Com has invested 0% in AbbVie Inc. (NYSE:ABBV). Horan Advsrs Ltd Company holds 2.17% or 39,630 shares in its portfolio. Northstar Investment Lc accumulated 11,843 shares or 0.21% of the stock. Bankshares Of Nova Scotia Trust accumulated 8,354 shares or 0.08% of the stock. Whalerock Point Ptnrs Ltd holds 0.14% or 4,374 shares in its portfolio. Adams Diversified Equity Fund owns 380,000 shares. Cambridge Trust owns 64,319 shares or 0.38% of their US portfolio. Delta Asset Ltd Llc Tn holds 3,314 shares or 0.04% of its portfolio. Retirement System Of Alabama has invested 0.58% in AbbVie Inc. (NYSE:ABBV). 6,300 are held by Adirondack Research And Mngmt. Advisors Asset Management invested in 0.79% or 528,992 shares. Eagle Advisors Limited Liability Corporation holds 10,450 shares. 43,990 are owned by Winslow Evans Crocker. Fifth Third Comml Bank has invested 0.9% in AbbVie Inc. (NYSE:ABBV). Natl Planning reported 0.93% stake.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $156.53 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 29.89 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

The stock decreased 0.95% or $0.35 during the last trading session, reaching $36.35. About 44,099 shares traded. Entegris, Inc. (ENTG) has risen 78.11% since March 23, 2017 and is uptrending. It has outperformed by 61.41% the S&P500.

Gmt Capital Corp holds 6.11% of its portfolio in Entegris, Inc. for 9.95 million shares. Rgm Capital Llc owns 1.93 million shares or 5.76% of their US portfolio. Moreover, Harvey Partners Llc has 5.47% invested in the company for 165,000 shares. The California-based Snyder Capital Management L P has invested 4.53% in the stock. Shapiro Capital Management Llc, a Georgia-based fund reported 6.89 million shares.

Ratings analysis reveals 75% of Entegris’s analysts are positive. Out of 4 Wall Street analysts rating Entegris, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $20.0 while the high is $26.0. The stock’s average target of $22.67 is -37.63% below today’s ($36.35) share price. ENTG was included in 4 notes of analysts from October 27, 2016. Needham initiated the stock with “Hold” rating in Monday, November 21 report. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, January 26. The stock of Entegris, Inc. (NASDAQ:ENTG) has “Buy” rating given on Thursday, October 27 by Dougherty & Company. The stock of Entegris, Inc. (NASDAQ:ENTG) has “Buy” rating given on Friday, February 10 by Goldman Sachs.

Since January 1, 0001, it had 0 buys, and 8 selling transactions for $9.53 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: